Should You Buy IDEXX Laboratories Inc (IDXX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/29
Buy for a beginner, long-term investor right now. Even though short-term technical momentum is soft, IDXX is a high-quality compounder with strong Q3 2025 growth and a broadly positive, rising analyst price-target backdrop (many targets $750–$850 vs ~$688 today). Hedge funds have meaningfully increased buying (+764% QoQ) and insiders are neutral. Options flow is bearish near-term (put-heavy volume), which fits the current pullback, but for a long-term buyer who doesn’t want to wait for a “perfect” entry, the current level near support is an attractive point to start/ add exposure.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Technical Analysis
Price ~$687.8 is below the pivot (~699.3), indicating the stock is currently trading in a weaker-than-neutral zone. MACD histogram (-1.754) is below zero and negatively expanding, signaling bearish momentum still building. RSI(6) at ~36 is near the lower end of neutral and approaching oversold conditions, consistent with a pullback rather than a strong uptrend.
Key levels: immediate support S1 ~683.8 (near current price); next support S2 ~674.2 if S1 breaks. Overhead resistance starts at the pivot ~699.3, then R1 ~714.8. With moving averages converging, the stock is in a consolidation/pullback phase; a sustained move back above ~699 would improve the near-term trend, while losing ~683 raises risk of a deeper dip toward ~674.
Analyst Ratings and Price Target Trends
Recent trend: price targets have generally moved up after strong Q3 results, with several Buy/Overweight/Outperform reiterations and raised targets (e.g., BTIG to $830, MS to $805, Stifel to $775, Leerink to $785). Barclays initiated Overweight with an $850 target, reinforcing a bullish long-term view. Neutral ratings remain (e.g., Piper, UBS, BofA), mainly centered on valuation—acknowledging operational strength but arguing the multiple is already rich.
Wall Street pros: best-in-class positioning in vet diagnostics, strong recurring revenue dynamics, improving macro/visit trends, innovation pipeline, and consistent execution.
Wall Street cons: premium valuation and limited near-term upside if growth cools; some caution that expectations are already high.
Influential/Political trading: no recent Congress trading data available; insiders show no significant recent trend (neutral).
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 792.78 USD with a low forecast of 750 USD and a high forecast of 850 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 792.78 USD with a low forecast of 750 USD and a high forecast of 850 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 687.740
Current: 687.740
